Abstract
In the early stages of the COVID-19 pandemic, the impact of SARS-CoV-2 on pregnant women remained poorly understood. This retrospective cohort study compared 31 pregnant women and 35 non-pregnant women of childbearing age in Wuhan, China, to evaluate clinical outcomes and the potential for vertical transmission. The study found that pregnant women often presented with atypical symptoms, such as a significantly lower incidence of fever, yet faced a higher risk of severe or critical illness. Notably, there was no evidence of vertical transmission in amniotic fluid, placenta, neonatal swabs, or breastmilk. Inflammatory markers, specifically the Neutrophil-to-Lymphocyte Ratio (NLR) and the Systematic Immune-Inflammation-based prognostic index (SII), were identified as effective tools for assessing disease severity in this population.
Introduction
During the initial outbreak of Coronavirus Disease 2019 (COVID-19), clinical data regarding its impact on pregnancy was critically scarce. Historical precedents with other coronaviruses, such as SARS-CoV and MERS-CoV, suggested that pregnant women might be more susceptible to severe morbidity and adverse neonatal outcomes due to physiological changes in the respiratory and immune systems. This study sought to characterize the clinical course of SARS-CoV-2 in pregnant patients and investigate the risk of vertical transmission from mother to fetus.
Methods
Researchers conducted a retrospective cohort study at Wuhan Union and Tongji hospitals between January 28 and February 28, 2020. The study population included:
- Participants: 31 pregnant women and 35 non-pregnant women (ages 20–40), all with PCR-confirmed SARS-CoV-2 infection.
- Clinical Assessment: Data collection included clinical symptoms, laboratory findings, and chest CT scans. Inflammatory indices, including the Neutrophil-to-Lymphocyte Ratio (NLR) and the Systematic Immune-Inflammation-based prognostic index (SII), were calculated to evaluate their predictive value for disease severity.
- Vertical Transmission Testing: To assess the risk of transmission to the fetus, RT-PCR testing was performed on amniotic fluid, placenta, neonatal throat and anal swabs, and breastmilk samples.
Clinical Presentation and the "Fever Gap"
A primary finding of the study was the "insidious" and atypical presentation of COVID-19 in pregnant patients. Most notably, pregnant women were significantly less likely to present with a fever compared to the non-pregnant cohort (54.8% vs. 87.5%, p = 0.006). This suggests that standard temperature-based screenings may be insufficient for identifying infected pregnant individuals.
Despite the milder initial symptoms, pregnant women were hospitalized sooner after the onset of symptoms (7.8 days vs. 13.2 days). This earlier hospitalization may reflect a lower threshold for medical intervention in pregnant patients rather than a more rapid progression of symptoms.
Disease Severity and Inflammatory Markers
While the initial symptoms were often subtle, the clinical outcomes for pregnant women were more severe. The study found that 32.3% of pregnant women developed severe or critical pneumonia, compared to only 11.4% of non-pregnant women (p = 0.039).
To help clinicians identify those at risk for severe disease, the researchers evaluated several inflammatory markers. They found that NLR and SII were significantly higher on admission in the severe/critical group compared to the moderate group (p < 0.001). These markers proved to be more sensitive indicators of severity in pregnant patients than Interleukin-6 (IL-6), a more commonly used inflammatory marker.
Neonatal Outcomes and Vertical Transmission
One of the most reassuring findings of the study was the lack of evidence for vertical transmission. All RT-PCR tests conducted on amniotic fluid, placenta, neonatal swabs, and breastmilk returned negative results.
Out of the 17 live births recorded during the study period, all neonates tested negative for SARS-CoV-2. While five of these births were premature, all occurred after 35 weeks of gestation, and the infants remained in stable condition. There were no instances of fetal death or neonatal infection reported in this cohort.
Discussion and Limitations
The study highlights that pregnancy may exacerbate the severity of COVID-19, even when initial symptoms like fever are absent. The hypercoagulable state observed in pregnant patients—characterized by higher D-dimer levels and shorter prothrombin times—further complicates the clinical picture and necessitates careful monitoring.
However, the study has several limitations:
- Sample Size: The small cohort (N=66) limits the generalizability of the findings.
- Selection Bias: The study only included hospitalized patients, which may skew the data toward more symptomatic or severe cases.
- Incomplete Data: Because many pregnancies were still ongoing at the time of the study, long-term outcomes for infections occurring in the first or second trimester were not fully captured.
Conclusion
Pregnant women with COVID-19 often present with atypical clinical symptoms, making early diagnosis challenging. Given the higher risk of severe disease in this population, clinicians should utilize markers like NLR and SII to monitor disease progression. While the absence of vertical transmission is encouraging, continued surveillance of pregnant women and their infants is essential to fully understand the long-term implications of SARS-CoV-2 infection during pregnancy.
Summary updated